Skip to content
StockMarketAgent
Direct answer
Zoetis is a dominant, mature compounder in the animal health space, benefiting from high switching costs, robust brand loyalty, and significant scale economies. With consistent mid-single-digit revenue growth and high operating margins (~37%), it generates strong and predictable free cash flow. Fair value range: low $109, high $170, with mid-point at $140.
Stock analysis

ZTS fair value $109–$170

By StockMarketAgent.AI team· supervised by
已分析: 2026-05-12下次更新: 2026-08-12Methodology v2.5Review: automatedArchetype: Mature compounder
View archive
股价
$76.94
▲ +62.83 (+81.66%)
公允价值
$140
$109–$170
评级
强力买入
confidence 88/100
上行空间
+81.7%
upside to fair value
安全边际
$118.80
MoS level · 15%
市值
$32.3B
P/E fwd 10.3
英文原文ZH
翻译期间显示英文原文
此报告尚未翻译。翻译队列赶上后请在几分钟内刷新。

§1 执行摘要

  • Composite fair value $140 with high case $170.
  • Implied upside of 81.7% to fair value.
  • Moat 9/10 · confidence 88/100 · Mature compounder.
  • Trades below fair value with a meaningful cushion to the midpoint.
Fair value
$140
Margin of safety
+45.0%
Confidence
88/100
Moat
9/10

Educational research only - not investment advice, an offer, or a trade instruction. Confirm current data and do your own due diligence before acting.

$76.94Price
Low $109.15
Mid $139.77
High $170.49

Zoetis is a dominant, mature compounder in the animal health space, benefiting from high switching costs, robust brand loyalty, and significant scale economies. With consistent mid-single-digit revenue growth and high operating margins (~37%), it generates strong and predictable free cash flow.

  • Intangible assets via unmatched patent
    Intangible assets via unmatched patent portfolio and brand loyalty.
  • High switching costs for veterinary
    High switching costs for veterinary practitioners integrated into the Zoetis ecosystem.
  • Cycle upside
    Accelerating pet humanization driving inelastic, premium companion animal healthcare spending.

§2 看空情景

A macroeconomic shock compressing discretionary pet spending combined with a cyclical livestock downturn would threaten historical 37% operating margins. The reverse DCFReverse DCFInverts a standard DCF: instead of solving for fair value, we solve for the growth rate the current price already implies — a useful test of whether the market's assumptions are reasonable. implies the market is already pricing in a structural decay (-2.52% perpetual growth), providing a massive margin of safetyMargin of safetyThe discount required between fair value and current price before we recommend buying. Typically 15% for wide-moat names, 25–35% for cyclicals or low-confidence cases. against such cyclical shocks.

该论点可能失败的方式

Margin Contraction

· Low

Operating margins sustainably drop below 35% due to generic competition and loss of pricing power.

FV impact
Valuation compresses to the $109.15 low-end threshold.

Livestock Headwinds

· Medium

Prolonged livestock disease cycle reduces the agricultural segment revenues structurally, dragging corporate growth.

FV impact
Mild drag on terminal value generation and forward EPS.

Macro Demand Shock

· Medium

Deep recession forces broad reduction in discretionary companion animal treatments and veterinary visits.

FV impact
Near-term EPS shock testing the $110 forward earnings scenario value.
需关注的早期预警信号
指标当前触发阈值
Operating margin contracting below 35% over two consecutive quarters.MonitorDeterioration versus the report thesis
Forward EPS growth turning negative.MonitorDeterioration versus the report thesis
ROIC dropping precipitously toward the 8.43% WACC.MonitorDeterioration versus the report thesis
Erosion of the 71.8% gross margin floor.MonitorDeterioration versus the report thesis
Accelerated generic approvals targeting core parasiticide or dermatology portfolios.MonitorDeterioration versus the report thesis

§3 财务历史

损益表 — 最近六期

项目2022-12-312023-12-312024-12-312025-12-31Trend
营业收入$8.08B$8.54B+5.7%$9.26B+8.4%$9.47B+2.3%+5.4%
毛利$5.63B$5.98B$6.54B$6.80B+6.5%
营业利润$2.93B$3.07B$3.39B$3.60B+7.1%
净利润$2.11B$2.34B+10.9%$2.49B+6.4%$2.67B+7.2%+8.1%
每股收益(摊薄)$4.49$5.07$5.47$6.02+10.3%
EBITDA$3.34B$3.67B$3.86B$4.07B+6.8%
研发$539.0M$614.0M$686.0M$698.0M+9.0%
销售管理费用$2.01B$2.15B$2.32B$2.38B+5.8%

质量评分

OCF / 净利润
1.09×
>1 表示盈利质量高
会计质量门槛
Fail
经行业调整门槛
ROIC
22.5%
投入资本回报率
个人订阅用户 — §4 及之后还有 11 个章节

阅读完整分析 — 还有 11 个章节。

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

涵盖每个股票的完整报告
24 个月的评级存档
关注列表简报 + 评级变更提醒
以任意语言导出 PDF + DOCX
开始免费试用
可随时取消。
REVERSE DCF FAQ

ZTS reverse dcf questions

  1. Reverse DCF for ZTS (ZTS) backs out the revenue or earnings growth rate the current share price implies, holding terminal value, margin, and discount-rate assumptions constant.
FAQ

ZTS — frequently asked questions

  1. Based on our latest analysis, ZTS looks meaningfully undervalued. The current price is $76.9 versus a composite fair-value midpoint of $140 (range $109–$170), which implies roughly 81.7% upside to the midpoint.
Related coverage

Names readers of ZTS also follow

Same archetype: mature-compounder